| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
,
*
Department of Molecular and Cellular Biology and Howard Hughes Medical Institute, and
Department of Chemistry and Biological Chemistry, Harvard University, Cambridge, MA 02138;
Laboratoire de Chimie Biophysique, Institut le Bel, Université Louis Pasteur, Strasbourg, France; and
Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland
We have determined high-resolution crystal structures of the complexes of HLA-A2 molecules with two modified immunodominant peptides from the melanoma tumor-associated protein Melan-A/Melanoma Ag recognized by T cells-1. The two peptides, a decamer and nonamer with overlapping sequences (ELAGIGILTV and ALGIGILTV), are modified in the second residue to increase their affinity for HLA-A2. The modified decamer is more immunogenic than the natural peptide and a candidate for peptide-based melanoma immunotherapy. The crystal structures at 1.8 and 2.15 Å resolution define the differences in binding modes of the modified peptides, including different clusters of water molecules that appear to stabilize the peptide-HLA interaction. The structures suggest both how the wild-type peptides would bind and how three categories of cytotoxic T lymphocytes with differing fine specificity might recognize the two peptides.
This article has been cited by other articles:
|
|
 |
|
  D. K. Cole, F. Yuan, P. J. Rizkallah, J. J. Miles, E. Gostick, D. A. Price, G. F. Gao, B. K. Jakobsen, and A. K. Sewell Germ Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell Receptor J. Biol. Chem., October 2, 2009; 284(40): 27281 - 27289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Derre, M. Ferber, C. Touvrey, E. Devevre, V. Zoete, A. Leimgruber, P. Romero, O. Michielin, F. Levy, and D. E. Speiser A Novel Population of Human Melanoma-Specific CD8 T Cells Recognizes Melan-AMART-1 Immunodominant Nonapeptide but Not the Corresponding Decapeptide J. Immunol., December 1, 2007; 179(11): 7635 - 7645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yagi, H. Hashizume, T. Horibe, Y. Yoshinari, M. Hata, A. Ohshima, T. Ito, M. Takigawa, A. Shibaki, H. Shimizu, et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous Peptide immunization. Cancer Res., October 15, 2006; 66(20): 10136 - 10144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Martinez-Hackert, N. Anikeeva, S. A. Kalams, B. D. Walker, W. A. Hendrickson, and Y. Sykulev Structural Basis for Degenerate Recognition of Natural HIV Peptide Variants by Cytotoxic Lymphocytes J. Biol. Chem., July 21, 2006; 281(29): 20205 - 20212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Colombetti, T. Fagerberg, P. Baumgartner, L. Chapatte, D. E. Speiser, N. Rufer, O. Michielin, and F. Levy Impact of Orthologous Melan-A Peptide Immunizations on the Anti-Self Melan-A/HLA-A2 T Cell Cross-Reactivity. J. Immunol., June 1, 2006; 176(11): 6560 - 6567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Thilo, P. Berglund, S. E. Applequist, J. W. Yewdell, H.-G. Ljunggren, and A. Achour Dissection of the Interaction of the Human Cytomegalovirus-derived US2 Protein with Major Histocompatibility Complex Class I Molecules: PROMINENT ROLE OF A SINGLE ARGININE RESIDUE IN HUMAN LEUKOCYTE ANTIGEN-A2 J. Biol. Chem., March 31, 2006; 281(13): 8950 - 8957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. E. Stewart-Jones, G. Gillespie, I. M. Overton, R. Kaul, P. Roche, A. J. McMichael, S. Rowland-Jones, and E. Y. Jones Structures of Three HIV-1 HLA-B*5703-Peptide Complexes and Identification of Related HLAs Potentially Associated with Long-Term Nonprogression J. Immunol., August 15, 2005; 175(4): 2459 - 2468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Y. Borbulevych, T. K. Baxter, Z. Yu, N. P. Restifo, and B. M. Baker Increased Immunogenicity of an Anchor-Modified Tumor-Associated Antigen Is Due to the Enhanced Stability of the Peptide/MHC Complex: Implications for Vaccine Design J. Immunol., April 15, 2005; 174(8): 4812 - 4820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Lee, G. Stewart-Jones, T. Dong, K. Harlos, K. Di Gleria, L. Dorrell, D. C. Douek, P. A. van der Merwe, E. Y. Jones, and A. J. McMichael T Cell Cross-Reactivity and Conformational Changes during TCR Engagement J. Exp. Med., December 6, 2004; 200(11): 1455 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Baxter, S. J. Gagnon, R. L. Davis-Harrison, J. C. Beck, A.-K. Binz, R. V. Turner, W. E. Biddison, and B. M. Baker Strategic Mutations in the Class I Major Histocompatibility Complex HLA-A2 Independently Affect Both Peptide Binding and T Cell Receptor Recognition J. Biol. Chem., July 9, 2004; 279(28): 29175 - 29184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Webb, M. A. Dunstone, W. Chen, M.-I. Aguilar, Q. Chen, H. Jackson, L. Chang, L. Kjer-Nielsen, T. Beddoe, J. McCluskey, et al. Functional and Structural Characteristics of NY-ESO-1-related HLA A2-restricted Epitopes and the Design of a Novel Immunogenic Analogue J. Biol. Chem., May 28, 2004; 279(22): 23438 - 23446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Rudolph, L. Q. Shen, S. A. Lamontagne, J. G. Luz, J. R. Delaney, Q. Ge, B. K. Cho, D. Palliser, C. A. McKinley, J. Chen, et al. A Peptide That Antagonizes TCR-Mediated Reactions with Both Syngeneic and Allogeneic Agonists: Functional and Structural Aspects J. Immunol., March 1, 2004; 172(5): 2994 - 3002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Guillaume, D. F. Legler, N. Boucheron, M.-A. Doucey, J.-C. Cerottini, and I. F. Luescher Soluble Major Histocompatibility Complex-Peptide Octamers with Impaired CD8 Binding Selectively Induce Fas-dependent Apoptosis J. Biol. Chem., February 7, 2003; 278(7): 4500 - 4509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ayyoub, A. Zippelius, M. J. Pittet, D. Rimoldi, D. Valmori, J.-C. Cerottini, P. Romero, F. Lejeune, D. Lienard, and D. E. Speiser Activation of Human Melanoma Reactive CD8+ T Cells by Vaccination with an Immunogenic Peptide Analog Derived from Melan-A/Melanoma Antigen Recognized by T Cells-1 Clin. Cancer Res., February 1, 2003; 9(2): 669 - 677. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
